Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20193172 | 0.85 | CHUK (0.54) | MAP3K14CHUK | |
| SCHEMBL19629497 | 0.81 | MAP3K14 (0.47) | MAP3K14CHUK | |
| SCHEMBL19629516 | 0.75 | CHUK (0.44) | MAP3K14CHUK | |
| SCHEMBL20193224 | 0.74 | CHUK (0.30) | CHUK | |
| SCHEMBL19629571 | 0.72 | MAP3K14 (0.55) | MAP3K14CHUK | |
| SCHEMBL19626307 | 0.70 | MAP3K14 (0.48) | MAP3K14CHUK | |
| SCHEMBL19626213 | 0.70 | CHUK (0.69) | MAP3K14CHUK | |
| SCHEMBL19626299 | 0.69 | MAP3K14 (0.47) | MAP3K14CHUK | |
| SCHEMBL19626217 | 0.69 | MAP3K14 (0.46) | MAP3K14CHUK | |
| SCHEMBL19629498 | 0.69 | MAP3K14 (0.37) | MAP3K14CHUK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9981962-B2 | Pyrazole derivatives as NIK inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-29 | — | — | US | disclosed |
| US-20170334900-A1 | NEW PYRAZOLE DERIVATIVES AS NIK INHIBITORS | ARGENTA DISCOVERY 2009 LIMITED (GB) | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170334900-A1 | NEW PYRAZOLE DERIVATIVES AS NIK INHIBITORS | MAP3K14, MAP3K15, MAP3K21 | MAP3K14 1/4885CHUK 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.